Shield Therapeutics plc (FRA:1JS)
Germany flag Germany · Delayed Price · Currency is EUR
0.1280
+0.0180 (16.36%)
At close: Jan 30, 2026

Shield Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-21.24-27.18-33.29-49.79-26.65-3.59
Depreciation & Amortization
0.450.710.372.122.192.97
Other Amortization
1.080.710.710.740.80.72
Asset Writedown & Restructuring Costs
---18.11--
Stock-Based Compensation
0.640.860.880.911.341.05
Other Operating Activities
4.883.551.251.40.010.51
Change in Accounts Receivable
-3.31-1.14-7.01-2.79-3.9-0.36
Change in Inventory
-2.34-2.46-1.450.22-0.35-0.59
Change in Accounts Payable
19.9110.471.917.272.69-2.83
Change in Other Net Operating Assets
4.987.71-0.48-0.78-0.870.2
Operating Cash Flow
5.05-6.77-37.13-22.59-24.73-1.91
Capital Expenditures
-0-0.04-0.24-0.06-0.5-
Sale (Purchase) of Intangibles
-2.72-2.39-2.71-2.22-2.29-0.03
Other Investing Activities
0.230.270.520.040.020
Investing Cash Flow
-2.49-2.16-2.43-2.25-2.78-0.03
Long-Term Debt Issued
-5.729.459.08--
Long-Term Debt Repaid
--0.21-5.99-0.15-0.1-0.07
Net Debt Issued (Repaid)
5.515.4923.458.93-0.1-0.07
Issuance of Common Stock
0.120.1226.820.1137.510.01
Other Financing Activities
-6.24-4.18-0.61-0.50.11-0.01
Financing Cash Flow
-0.611.4349.668.5337.52-0.06
Foreign Exchange Rate Adjustments
0.760.070.45-1.132.410.36
Miscellaneous Cash Flow Adjustments
---4.5--
Net Cash Flow
2.72-7.4210.55-12.9412.43-1.64
Free Cash Flow
5.05-6.81-37.37-22.66-25.23-1.91
Free Cash Flow Margin
12.17%-21.15%-285.56%-411.98%-1226.73%-13.48%
Free Cash Flow Per Share
0.01-0.01-0.05-0.10-0.12-0.02
Cash Interest Paid
5.923.950.610.40.060.01
Cash Income Tax Paid
1.760.760.72-0.71-0.80.12
Levered Free Cash Flow
-0.58-12.05-28.96-12.7-17.680.21
Unlevered Free Cash Flow
3.17-9.63-28.33-12.45-17.680.21
Change in Working Capital
19.2414.58-7.023.93-2.43-3.58
Source: S&P Global Market Intelligence. Standard template. Financial Sources.